Aegis Awarded New Patent for Stable Human Growth Hormone Formulations
Posted on: Wednesday, 17 September 2008, 12:00 CDT
Aegis Therapeutics, a drug delivery technology company, has received new US patent that provides broad protection for stabilized human growth hormone formulations.
The Aegis ProTek technology has been employed to create stabilized formulations of human growth hormone (hGH), insulin, antibodies, and other protein drugs that remain unchanged even after continuous agitation for many weeks or months at elevated temperatures.
The patented formulations are said to be suitable for intranasal delivery via a simple metered nasal spray as well as by standard injection or external drug infusion pump.
Aegis ProTek technology is expected to provide patients with safer, more convenient, non-injectable delivery options while extending the effective patent life of hGH and other protein drugs.
Human growth hormone is a recombinant protein drug used in the treatment of pediatric and adult patients who have inadequate secretion of normal endogenous growth hormone.
Source: Datamonitor
Related Articles
- New sepsis drug to face human trials
- Hormone Disorder Drug Could Help Drinkers Stay Sober
- Rearchers Discover Proteins Regulating Human Beta cell Replication
- Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
- Delivering Therapeutic Proteins - An Analysis of the Special Formulations and Delivery Strategies Required for Complex Therapeutic Substances
- Protein in Human Embryonic Stem Cells Controls Malignant Tumor Cells
- Litigation Settlement Reached Over Insmed Growth Drug
- Growth Drug Melts Bad Fat in HIV Patients
- Protein Drugs Tied to Formulation and Delivery Advances
- Slow Sales of Hormone-Replacement Drug Force Wyeth to Shut Down Plant
 |
 |
User Comments (0)
RSS Feeds